Nirmatrelvir-ritonavir versus placebo-ritonavir in individuals with long COVID in the USA (PAX LC): a double-blind, randomised, placebo-controlled, phase 2, decentralised trial.

Sawano M, Bhattacharjee B, Caraballo C, Khera R, Li SX, Herrin J, Christian D, Coppi A, Warner F, Holub J, Henriquez Y, Johnson MA, Goddard TB, Rocco E, Hummel AC, Mouslmani MA, Hooper WB, Putrino DF, Carr KD, Charnas L, De Jesus M, Nepert D, Abreu P, Ziegler FW 3rd, Spertus JA, Iwasaki A, Krumholz HM

Open source

DOI: 10.1016/s1473-3099(25)00073-8
Published: 2025 Aug
Container: The Lancet. Infectious diseases
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1473-3099-25-00073-8,
  title = {Nirmatrelvir-ritonavir versus placebo-ritonavir in individuals with long COVID in the USA (PAX LC): a double-blind, randomised, placebo-controlled, phase 2, decentralised trial.},
  author = {Sawano M and Bhattacharjee B and Caraballo C and Khera R and Li SX and Herrin J and Christian D and Coppi A and Warner F and Holub J and Henriquez Y and Johnson MA and Goddard TB and Rocco E and Hummel AC and Mouslmani MA and Hooper WB and Putrino DF and Carr KD and Charnas L and De Jesus M and Nepert D and Abreu P and Ziegler FW 3rd and Spertus JA and Iwasaki A and Krumholz HM},
  year = {2025},
  journal = {The Lancet. Infectious diseases},
  doi = {10.1016/s1473-3099(25)00073-8},
  url = {https://doi.org/10.1016/s1473-3099(25)00073-8}
}

RIS

TY  - JOUR
TI  - Nirmatrelvir-ritonavir versus placebo-ritonavir in individuals with long COVID in the USA (PAX LC): a double-blind, randomised, placebo-controlled, phase 2, decentralised trial.
AU  - Sawano M
AU  - Bhattacharjee B
AU  - Caraballo C
AU  - Khera R
AU  - Li SX
AU  - Herrin J
AU  - Christian D
AU  - Coppi A
AU  - Warner F
AU  - Holub J
AU  - Henriquez Y
AU  - Johnson MA
AU  - Goddard TB
AU  - Rocco E
AU  - Hummel AC
AU  - Mouslmani MA
AU  - Hooper WB
AU  - Putrino DF
AU  - Carr KD
AU  - Charnas L
AU  - De Jesus M
AU  - Nepert D
AU  - Abreu P
AU  - Ziegler FW 3rd
AU  - Spertus JA
AU  - Iwasaki A
AU  - Krumholz HM
PY  - 2025
JO  - The Lancet. Infectious diseases
DO  - 10.1016/s1473-3099(25)00073-8
UR  - https://doi.org/10.1016/s1473-3099(25)00073-8
ER  -

APA

M, S., B, B., C, C., R, K., SX, L., J, H., D, C., A, C., F, W., J, H., Y, H., MA, J., TB, G., E, R., AC, H., MA, M., WB, H., DF, P., KD, C., L, C., M, D. J., D, N., P, A., 3rd, Z. F., JA, S., A, I., & HM, K. (2025). Nirmatrelvir-ritonavir versus placebo-ritonavir in individuals with long COVID in the USA (PAX LC): a double-blind, randomised, placebo-controlled, phase 2, decentralised trial.. The Lancet. Infectious diseases. https://doi.org/10.1016/s1473-3099(25)00073-8

Source records

pubmed · retrieved 2026-09-26T09:25:08.549Z